

Please amend the subject application as follows:

**Amendment to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of the Claims:**

1. (Currently Amended) A composition which comprises:
  - (a) a conjugate of i) a derivative of a fucosyl GM1 ganglioside derivative which comprises a converted ceramide portion, which differs from the ceramide portion of the fucosyl GM1 ganglioside solely by having an aldehyde group in place of a double bond, and to ii) Keyhole Limpet Hemocyanin, wherein the derivative of fucosyl GM1 ganglioside is covalently conjugated to Keyhole Limpet Hemocyanin by a covalent bond between an amino group of Keyhole Limpet Hemocyanin and the aldehyde group of the converted ceramide portion of the fucosyl GM1 ganglioside; an immunogenic protein,
  - (b) ~~QS-21; a carbohydrate derived from the bark of a Quillaja saponaria Molina tree,~~  
and
  - (c) a pharmaceutically acceptable carrier,  
wherein the fucosyl GM1 ganglioside derivative:Keyhole Limpet Hemocyanin molar ratio in the conjugate is from 400:1 to 1400:1; and the

~~amounts of such~~ conjugate and QS-21 are each  
present in the composition in an amount such  
~~adjuvant being~~ effective to stimulate or enhance  
antibody production in a subject. [[,]]

~~wherein, in the conjugate the ganglioside~~  
~~derivative is conjugated to the immunogenic~~  
~~protein through a ceramide portion of the~~  
~~ganglioside.~~

2.-5. (Cancelled)

6. (Currently Amended) The composition of claim 1,  
wherein the amount of the conjugate ~~ganglioside~~ is  
~~an amount~~ between about 3 µg and about 100 µg.

7. (Currently Amended) The composition of claim ~~5~~ 1,  
wherein the amount of QS-21 is ~~an amount~~ between  
about 30 µg and about 100 µg.

8. (Previously Presented) The composition of claim 1,  
wherein the subject is a human.

9.-10. (Cancelled)

11. (Currently Amended) A method of enhancing antibody  
production in a subject which comprises  
administering to the subject an effective antibody  
producing amount of ~~the~~ a ~~composition of claim 1,~~  
comprising:

(a) a conjugate of i) a derivative of a  
fucosyl GM1 ganglioside which comprises a

converted ceramide portion, which differs from the ceramide portion of the fucosyl GM1 ganglioside solely by having an aldehyde group in place of a double bond, and ii) Keyhole Limpet Hemocyanin, wherein the derivative of fucosyl GM1 ganglioside is covalently conjugated to Keyhole Limpet Hemocyanin by a covalent bond between an amino group of Keyhole Limpet Hemocyanin and the aldehyde group of the converted ceramide portion of the fucosyl GM1 ganglioside;

(b) QS-21; and

(c) a pharmaceutically acceptable carrier, wherein the fucosyl GM1 ganglioside derivative:Keyhole Limpet Hemocyanin molar ratio in the conjugate is from 400:1 to 1400:1; and the conjugate and QS-21 are each present in the composition in an amount effective to stimulate or enhance antibody production in a subject. ~~so as to thereby enhance antibody production in the subject.~~

12.-13. (Cancelled)

14. (Currently Amended) A method of treating a small cell lung cancer in a subject which comprises administering to the subject an effective small cell lung cancer treating amount of a ~~the~~ composition ~~of claim 1,~~ comprising:

(a) a conjugate of i) a derivative of a fucosyl GM1 ganglioside which comprises a

converted ceramide portion, which differs from the ceramide portion of the fucosyl GM1 ganglioside solely by having an aldehyde group in place of a double bond, and ii) Keyhole Limpet Hemocyanin, wherein the derivative of fucosyl GM1 ganglioside is covalently conjugated to Keyhole Limpet Hemocyanin by a covalent bond between an amino group of Keyhole Limpet Hemocyanin and the aldehyde group of the converted ceramide portion of the fucosyl GM1 ganglioside;

(b) QS-21; and

(c) a pharmaceutically acceptable carrier, wherein the fucosyl GM1 ganglioside derivative:Keyhole Limpet Hemocyanin molar ratio in the conjugate is from 400:1 to 1400:1; and the conjugate and QS-21 are each present in the composition in an amount effective to so as to thereby treat the small cell lung cancer in the subject.

15.-16. (Cancelled)